Lumos Pharma | NLNK - Ativo Circulante



Ativo Circulante Alterar Data
Agenus USD 133.44M 514K 2025-12
Alterity Therapeutics Limited AUD 37.91M 15.92M 2025-12
Bristol-Myers Squibb USD 35.63B 2.41B 2025-09
Capricor Therapeutics USD 322.94M 221.99M 2025-12
Celldex Therapeutics USD 534.66M 69.68M 2025-12
Cipla INR 249.18B 16.3B 2025-09
Clal Biotechnology ILS 14.69M 1.95M 2023-12
Compugen USD 148.02M 59.1M 2025-12
CSL USD 11.85B 1000K 2025-12
Eli Lilly USD 55.63B 6.44B 2025-12
Grifols EUR 5.96B 316.31M 2025-12
Incyte USD 5.02B 746.01M 2025-12
Intrexon USD 23.72M 45.04M 2024-06
Merck USD 47.56B 10.49B 2025-09
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Pfizer USD 46.92B 3.22B 2025-09
Prothena USD 315.19M 24.78M 2025-12
Sarepta Therapeutics USD 2.54B 184.37M 2025-12